Three reports, published yesterday, show that disparities in the time it takes for European patients to access new medicines persist. Across the region, the average time to patient access is 531 days. Ranging from 126 days in Germany to 804 days in neighbouring Poland.

"The reasons why patients in one part of Europe wait longer for a new medicine than those in another country are almost always a combination of factors. They differ across therapy areas, they differ from country to country. It is why access issues cannot be solved through EU innovation legislation but require action from multiple actors, including member states, in order to make progress." said Nathalie Moll, EFPIA Director General.

Discover more. 

Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase with a few symptoms.

#Imagine if healthcare systems in Europe detected and diagnosed AD in its early stages, which is when treatments are more effective.

Read more on how we can work towards this future.

Watch the recording of the webinar series, organised by Cancer Patients Europe (CPE).